Walmart copes with fallout from revelations of bribery in Mexico.

Chrysler aims new Dodge Dart at Millennials, opens new door to get suppliers' best ideas, and returns to China with new concept vehicle at Beijing Auto Show.

Disney accepts resignation of film chief after loss on John Carter, while more companies hire Disney Institute to help with customer service.

Amylin is searching for a buyer.

Audi sees demand surge in China and U.S.

Avon arrives late at e-commerce.Continue reading...

Amazon plans to republish James Bond novel series.

Apple and Samsung are ordered into a patent-settlement conference, while Apple pressures Beijing with iPad snub.

Eatzi's expands into new locations.

Berkshire Hathaway will remain firmly under Warren Buffett's control as he undergoes prostate-cancer treatment.

Best Buy sees CEO search influenced by founder.

Bristol-Myers Squibb tops Corporate Responsibility Magazine's Best Corporate Citizens 2012 ranking.

Chevrolet touts Volt with Klout.

Citicorp sees executive pay plan ovewhelmingly rejected by shareholders.Continue reading...

AT&T faces possible union walkout.

Ally promotes financial literacy.

Audi, BMW and Mercedes-Benz reap luxury-sales gains in China.

Burger King plans to go public again in surprise move, selling $1.4 billion stake.

Coca-Cola remains UK's top grocery brand.

Delta counters industry gloom with late-March surge.

Facebook countersues Yahoo in patent spat.

Fisker debuts new plug-in as manufacturing plans hang in doubt.

Groupon hit with shareholder suit.Continue reading...

Angry Birds is heading to space.

Apple threatens to sue China's Proview over iPad trademark dispute.

Boeing competes for Asia orders worth $10 billion.

Danone and Nestle work to overcome antitrust obstacles in their bids for Pfizer infant-nutrition unit.

David Yurman and other brands see uptick in sales of men's accessories.

Fiat retunes U.S. marketing after 2011 problems while erstwhile spokeswoman Jennifer Lopez turns to lots of other brand deals.

Google launches Latitude Leaderboards, puts Foursquare on notice.Continue reading...

American Airlines parent AMR plans to cut 13,000 jobs and pensions.

Apple's iPhone 5 may be coming in June.

Benetton family plans to take retailer private.

Deutsche Bank profit tumbles on European debt crisis.

Facebook sets stage for historic IPO as valuation game begins.

GM cancels half of upfront ad commitments in cost-cutting move.

Google responds to Microsoft criticism of privacy policies.Continue reading...

Apple's blockbuster quarter puts iPhone ahead of Google smartphones in the U.S.

Brinker International expands value strategy at Chili's.

Christian Louboutin makes the IP case for its red-soled shoes.

Davos kicks off with worries about eurozone crisis.

Del Frisco's Restaurant plans IPO.

Fiat launches ad for new Panda into Italian austerity zeitgeist.Continue reading...

Airbus raises prices of A320neo plane amid strong demand, as Boeing threatens to compete better in 2012 .

AirTran must reinstate whistleblower pilot.

American Express invests $125 million in China mobile payments startup.

Apple eases into corporate market with Macs, while textbook push draws interest.

BankUnited draws bids from TD Bank and others.

Beyonce and Jay-Z challenged by Blue Ivy trademark applicant.

Burberry sales surge on international demand.Continue reading...

Merck & Co.’s HIV-fighting drug Isentress has been on the market for adults since October of 2007. Now the FDA is letting Merck market the product to children and teens, the Wall Street Journal reports.

Isentress is what’s known as an “HIV integrase inhibitors,” that “work(s) by interfering with the virus's ability to replicate itself,” the Journal notes. 

U.S. clinical trials were done with the drug on 96 children and teens between the ages of 2 and 18 years old with HIV. It “found that 53% of these patients had an undetectable amount of HIV in their blood after 24 weeks of treatment with the drug,” WSJ adds.

Merck also is joining five other drug manufacturers to provide discounts on HIV drugs to state drug-assistance programs, according to FiercePharma.com. Starting this week, Merck is discounting Isentress through 2013 to help out the National Alliance of State and Territorial AIDS Directors.

"With the economy the way it is, there are many more people without jobs and many more people who are qualifying for the programs," said Murray Penner, the organization's deputy executive director. "The need has ballooned."

Johnson & Johnson, Bristol-Myers Squibb, Gilead Sciences, Boehringer Ingelheim and the Pfizer/GlaxoSmithKline joint venture ViiV Healthcare have all also discounted drugs for the state programs.